The cash went to Viacyte, Inc., of San Diego, Ca., slightly more than $10.1 million for a diabetes project, and to bluebirdbio of Cambridge, Mass ,
$9.4 million for a B-thalassemia effort. CIRM directors approved the
awards with virtually no discussion. The agency is limited to funding research by the companies that is performed in California
The awards are part of the agency's
push to commercialize stem cell research and engage industry more
closely. All of the six applicants came from industry. However, the
firms that were turned down were not identified with the exception of Athersys,
Inc., of Cleveland, Ohio.
CIRM Director Steve Juelsgaard asked for a
discussion of an appeal by Athersys, Inc., of Cleveland, Ohio, whose
application was rejected by reviewers who scored it at 60 out of 100.
The two winners had scores of 88 and 73. .However, following a brief
look at the application, the board rejected Athersys' application along with other
proposals turned down by reviewers. .
Click on this link for the CIRM press release on
the awards.
No comments:
Post a Comment